The Filing Desk

Xeris Biopharma

XERS · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

XERS · Last close · November 13, 2026
$16.66
Value Xeris Biopharma yourself

Xeris Biopharma's revenue rose 43.7% to $292 million in fiscal 2025. Its operating margin was 8.5%, up from −16.6% a year earlier. The diluted share count rose 17.7%.

XERIS BIOPHARMA HOLDINGS, INC. Latest fiscal year ended December 31, 2025 10-K filed March 2, 2026 · 0001867096-26-000016 Updated
Revenue
$292M
43.7%
Operating margin
8.5%
25.1 pts
Net income
$1M
 
Free cash flow
—
 
Return on capital
19.6%
41.5 pts
Market cap
$3.2B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Xeris Biopharma does

Xeris Biopharma is a pharmaceutical company that develops and sells treatments for long-term hormone and nerve disorders in the United States. It sells three medicines. Recorlev treats high cortisol levels in adults with Cushing's syndrome when surgery is not an option or has not cured it. Gvoke is a ready-to-use liquid glucagon for severe low blood sugar in people with diabetes age two and older. Keveyis treats primary periodic paralysis, a rare genetic disorder that can cause extreme muscle weakness.

The company earns its revenue from selling these three products. It calls maximizing them its top priority.

Its main product in development is XP-8121, a once-weekly injection under the skin of levothyroxine, a thyroid hormone, for hypothyroidism. Xeris says it plans to start a Phase 3 trial in 2026. The name Xeris comes from a Greek word meaning dry. It uses its own non-water-based drug formulations, XeriSol and XeriJect, to make drugs that can be injected, and it is looking for partners that would use that technology on other companies' drugs.

Its biggest risks, as it describes them

  • A limited history of selling drugs and large losses since it began.
  • It may need more capital, which could dilute shareholders or not be available.
  • Cash may not be enough to pay interest and principal on its debt.
  • Its business depends on the commercial success of its products and candidates.
  • Competition, and needing strong sales, marketing and distribution to sell its medicines.
From Xeris Biopharma's annual report on Form 10-K, filed March 2, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1021227272111
Debt incl. finance leases88187191232220
Net debt (negative means net cash)−1465118160109
Net debt to EBITDA————4.2x
Debt to equity0.9x4.1x———
Interest coverage−16.0x−5.8x−1.6x−1.1x0.9x
Current ratio1.8x2.5x1.6x1.7x2.2x
Quick ratio1.6x2.2x1.2x1.2x1.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Xeris Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Xeris Biopharma shares on the open market, and 9 insiders sold $4.7 million, $3.7 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 28, 2026Kevin McCullochSee RemarksSold plan25,000$10.00$250,000Form 4
Sep 1, 2026Beth HechtSee RemarksSold plan16,666$8.49$141,494Form 4
Sep 1, 2026Kevin McCullochSee RemarksSold plan15,000$8.49$127,350Form 4
Sep 1, 2026Steven PieperSee RemarksSold plan5,000$8.50$42,500Form 4
Aug 12, 2026Steven PieperSee RemarksSold plan5,000$8.50$42,500Form 4
Aug 3, 2026Beth HechtSee RemarksSold plan16,666$8.01$133,495Form 4
Aug 3, 2026Kevin McCullochSee RemarksSold plan15,000$8.02$120,300Form 4
Jul 7, 2026Steven PieperSee RemarksSold plan27,600$8.52$235,152Form 4
Jul 6, 2026Steven PieperSee RemarksSold plan17,400$8.50$147,900Form 4
Jul 1, 2026Kevin McCullochSee RemarksSold plan90,000$8.03$722,700Form 4
Jul 1, 2026Beth HechtSee RemarksSold plan16,666$8.03$133,828Form 4
Jun 4, 2026Dawn HalkuffDirectorSold plan20,000$6.09$121,800Form 4
The latest 12 of 27 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 84 of 87 of 8
Rule of 40———
Altman Z''−5.93−6.20−2.99
Accruals ratio−4.6%−5.5%−8.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassFailPass
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score4 of 84 of 87 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Xeris Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Xeris BiopharmaFY2543.7%8.5%—19.6%4.2x7
Rigel PharmaceuticalsFY2564.2%42.6%—91.3%−0.8x7Compare
Ironwood PharmaceuticalsFY25−15.7%33.3%42.9%———Compare
EvolusFY2511.6%−11.0%−15.4%−47.2%—2Compare
Aurinia PharmaceuticalsFY2520.4%37.1%47.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue2050110164203292
Revenue growth—142.7%122.3%48.7%23.9%43.7%
Gross profit——————
Research and development212521222631
Operating income−84−115−82−44−3425
Net income−91−123−95−62−551
Diluted EPS (US$)−2.14−1.55−0.70−0.45−0.370.00
Diluted shares (millions)4379136138147173
Cash flow
Cash from operations−81−96−103−47−3729
Capital expenditure01————
Free cash flow−81−97————
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation81112111822
Balance sheet at fiscal year end
Cash and short-term investments1341021227272111
Debt incl. finance leases8788187191232220
Total assets159304344323323384
Total liabilities125209299329353370
Shareholders' equity349545−7−3014
Margins and ratios
Gross margin——————
Operating margin−408.8%−232.2%−74.3%−26.9%−16.6%8.5%
Net margin−446.0%−247.5%−85.9%−38.0%−27.0%0.2%
Free cash flow margin−396.1%−194.8%————
Rule of 40 (growth + FCF margin)—−52.2%————
Return on capital—−268.1%−67.7%−31.3%−21.9%19.6%
Return on equity—−190.3%−134.8%−324.2%——
Return on assets—−53.0%−29.2%−18.7%−17.0%0.2%
Net debt to EBITDA—————4.2x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Xeris Biopharma's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Xeris Biopharma.